Regeneron Partners with Trump Administration to Lower Drug Prices Amid Gene Therapy Approval
Regeneron's New Agreement
Regeneron has recently entered into an agreement with the Trump administration aimed at reducing drug prices for certain American patients. This announcement coincided with the federal approval of its innovative gene therapy for hearing loss.
Details of the Agreement
What the Deal Covers
On Thursday, it was revealed that Regeneron will lower prices for specific drugs in the U.S. as part of Trump's initiative to ensure that American drug prices align with the lowest rates found in other developed nations.
RapidResponse47
2047401553267445878
RapidResponse47
2047398491308146781
This agreement also provides Regeneron with a three-year exemption from tariffs, including Trump's proposed tariffs of up to 100% on certain pharmaceutical products. The White House has indicated that 17 such agreements have been established with various drug and biotech firms, with additional negotiations ongoing, as confirmed by CMS deputy administrator Chris Klomp during a recent event.
Breakthrough in Gene Therapy
The Gene Therapy Breakthrough
The timing of this agreement is particularly significant. Just hours prior to the announcement, the FDA granted approval for Regeneron's gene therapy, Otarmeni, which has shown promise in restoring hearing for a select group of deaf children during clinical trials. This therapy addresses a rare genetic condition that inhibits the production of a crucial protein for hearing.
For patients who have relied on cochlear implants, this therapy marks a substantial advancement. Regeneron has stated that it will provide the therapy free of charge to eligible patients in the U.S. following its approval. Analysts from Piper Sandler have projected that this gene therapy could potentially achieve peak annual sales of approximately $130 million, according to a CNBC report.
A Broader Initiative
Part of a Bigger Push
Regeneron is now part of a growing number of pharmaceutical companies that have made pricing adjustments under agreements with the Trump administration. Other major companies, including Pfizer, Eli Lilly, and Amgen, have also committed to reducing their prices. The administration is actively working to align U.S. drug costs with those of other affluent countries, and the tariff exemptions seem to be a significant incentive for companies to engage in these agreements.